Company History

Company History

Our Founding Spirit

1954: Established Fuji Yakuhin Shogyo

With the enactment of the Pharmaceutical Affairs Law in 1948 (current Pharmaceutical and Medical Device Act*), post-war reconstruction progressed and the demand for high-quality pharmaceutical products increased. Under such circumstances, in April 1954, the late Seiichi Imai established Fuji Pharmaceutical by himself in Toshima-ku, Tokyo, drawing on his knowledge and experience in pharmaceutical sciences, and started selling pharmaceutical products. This was the beginning of our company.

Imai valued making use of what he had learned through challenges and learning for the benefit of people and society, and at the time of founding the company, he was torn between creating an educational institution and a pharmaceutical company. In the end, he chose the pharmaceutical industry as a place to realize his idea that many people can learn and grow and use their learning to contribute to society in pharmaceutical companies.

* Abbreviation of "Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices"

1959: Established Fuji Seiyaku Kogyo

Five years after its founding, the company expanded its business by building a pharmaceutical plant at Imai's home in Mizuhashi-machi, Nakaniikawa-gun, Toyama Prefecture (now the Mizuhashi area of Toyama City) and began manufacturing pharmaceutical products in-house (at home). In April 1959, Fuji Pharmaceutical Co., Ltd. was established.
Seiichi Imai was in charge of sales mainly in Tokyo, and his wife Michiko Imai was in charge of manufacturing in Toyama, marking the start of the current system of the Tokyo Head Office and Toyama Plant.

1965: Established the present Fuji Pharma Co., Ltd.

In 1959, the current National Health Insurance Act, which provides for a universal health insurance system, was established. Subsequent improvements in this system led to an increase in demand for medical care, which led to a shift in the focus from over-the-counter drugs to ethical pharmaceuticals.
Under these circumstances, Seiichi Imai dreamed, "Through our work in ethical pharmaceuticals, we, as well as each of our colleagues, will gain a lot of experience, increase what we can contribute to medical care, develop together with our colleagues, our customers as doctors, and our business partners, and expand the circle of happiness for everyone" and in April 1965 reorganized Fuji Pharmaceutical Co., Ltd. and established Fuji Pharma Co., Ltd. (Shareholders: 7 relatives, capital: 2.5 million yen) in Adachi-ku, Tokyo.

Our company decided to enter the field of Women's Healthcare. Since our founding, we have had the desire to contribute to an area in which many people have needs but have not received sufficient support. The market of Women's Healthcare is small, and there are many products such as hormone drugs that are difficult to manage and highly specialized, making it difficult for other companies to enter this field. That's why we decided to take on the challenge of advancing this underdeveloped field.

The thoughts and dreams of Seiichi Imai at that time are still enshrined in the corporate philosophy of "We help people lead healthy lives by offering excellent pharmaceuticals" and "Our corporate growth is proportional to our personal growth".


  • Old brand mark
  • Price List at that time

◆2005: First year of "second foundation" / Creation of new brand mark

We designated 2005, the 40-year anniversary of our establishment in 1965, as the first year of our company's "second foundation" and created a new brand mark to express the thoughts and philosophy of our company.
The sphere that forms the basis of our company brand mark represents a sense of unity with all of our stakeholders, including customers, shareholders, employees, and communities/society. The streamlined shape that forms the "F" represents the leap and growth of people and companies. Furthermore, the sparkle of the sphere expresses the expectations from society and the creativity from inside.

History of Our Company

April 1954Established Fuji Pharmaceutical in Toshima-ku, Tokyo
April 1959Established Fuji Pharmaceutical Co., Ltd.
April 1965Reorganized as a joint-stock company and established Fuji Pharma Co., Ltd. in Adachi-ku, Tokyo
July 1973Opened Tokyo Branch and Nagoya Branch
October 1973Built a factory in Toyama City and moved there
November 1973Completed the Research Building and Distribution Center on the premises of Toyama Plant
April 1974Opened Osaka Branch and Fukuoka Branch
November 1976Opened Toyama Branch
March 1979Opened Sapporo Branch
April 1979Moved Head Office to 1-9-11 Shikahama, Adachi-ku, Tokyo
September 1983Opened Sendai Branch
July 1987Established the injection medicine building (current Pharmaceutical Manufacturing Building No. 1) on the premises of Toyama Plant
July 1994Established the injection medicine plant (current Pharmaceutical Manufacturing Building No. 3) on the premises of Toyama Plant
June 1995Registered shares for over-the-counter trading with Japan Securities Dealers Association
July 1997Entrusted logistics operations, and established Logistics Center in Ota-ku, Tokyo
December 1998Hirofumi Imai assumed the position of president
May 2002Established the injection medicine plant (current Pharmaceutical Manufacturing Building No. 2) in the premises of Toyama Plant
July 2003Moved Head Office and Tokyo Branch to Chiyoda-ku, Tokyo
December 2004Canceled over-the-counter registration with Japan Securities Dealers Association and listed on JASDAQ Stock Exchange
April 2005Created new brand mark and redesigned website for the "second foundation"
April 2006Established the tablet plant (current Pharmaceutical Manufacturing Building No. 4) on the premises of Toyama Plant
February 2009Started discussions on a business alliance with Terumo Corporation and formed a capital alliance
April 2010Listed on Osaka Securities Exchange JASDAQ market following the merger of JASDAQ Stock Exchange and Osaka Securities Exchange
October 2010Listed on Osaka Securities Exchange JASDAQ (Standard) following market integration of Osaka Securities Exchange Hercules market, Osaka Securities Exchange JASDAQ, and Osaka Securities Exchange NEO market
March 2011Moved Head Office and Tokyo Branch within the same ward
June 2011Established the injection medicine plant (current Pharmaceutical Manufacturing Building No. 5) on the premises of Toyama Plant
July 2011Issued new shares through public offering and third-party allotment
October 2011Delisted from Osaka Securities Exchange JASDAQ (Standard)
July 2012Listed on Tokyo Stock Exchange First Section
October 2012Acquired OLIC (Thailand) Limited, Thailand's largest contract pharmaceutical manufacturer, as a subsidiary
April 2013Completed Toyama Research and Development Center near Toyama Plant
March 2014Concluded capital and business alliance agreement with Mitsui & Co., Ltd.
April 2016Eiji Takemasa assumed the position of president
January 2017OLIC (Thailand) Limited established the injection medicine plant and warehouse building on its factory premises in Thailand
October 2019Takayuki Iwai assumed the position of president
February 2021Terminated capital alliance with Mitsui & Co., Ltd.
April 2022Transferred from Tokyo Stock Exchange First Section to Prime Market owing to the revision of the market segmentation of Tokyo Stock Exchange
June 2022Established a new tablet building (Pharmaceutical Manufacturing Building No. 6) on the premises of Toyama Plant
July 2022Established a new packaging building (Pharmaceutical Manufacturing Building No. 7) and a new warehouse building on the premises of Toyama Plant
October 2024Shuhei Morita assumed the position of president
March 1974Launched the estrogenic preparation ESTRIOL tablets, our company's first preparation in the field of Women's Healthcare
March 1974Launched the oral progesterone preparation MEDROXYPROGESTERONE ACETATE tablets
August 1981Obtained the approval of in-vitro diagnostic agent Plex
July 1985Obtained the approval of gonadotropin HMG Fuji
January 1986Obtained the approval of human chorionic gonadotropin preparation HCG Fuji
July 1999Launched follicle stimulating hormone preparation FOLYRMON-P injections
July 2000Launched GnRH derivative preparation BUSERELIN nasal solution
July 2007Signed an agreement with Nobelpharma Co., Ltd. for the marketing of dysmenorrhea treatment agent LUNABELL tablets
* At the time of signing, the product name was Endobell tablets.
June 2008Launched the dysmenorrhea treatment agent LUNABELL combination tablets (new drug)
August 2011Launched the oral contraceptive Favoir tablets
May 2012Transferred the sales of transdermal estradiol preparation l'estrogel
* The manufacturing and marketing approval was succeeded from Shiseido Company, Limited in January 2020.
June 2012Launched the oral contraceptive Labellefille tablets
September 2013Launched the dysmenorrhea treatment agent LUNABELL tablets ULD (new drug)
December 2013Succeeded the manufacturing and marketing approval of Lutoral tablets and Flagyl vaginal tablets and transferred the sales of Norluten tablets and Clomid tablets from Shionogi & Co., Ltd.
February 2016Launched the natural progesterone preparation UTROGESTAN vaginal capsules 200mg (new drug)
June 2017Launched the endometriosis treatment agent and treatment agent for pain relief associated with uterine adenomyosis DIENOGEST tablets
March 2019Launched the emergency contraception LEVONORGESTREL tablets
September 2021Launched the natural progesterone preparation F-meno capsules 100 mg (new drug)
December 2021Formed a sales partnership with Ferring Pharmaceuticals Co., Ltd. For cervical ripening agent PROPESS vaginal inserts (new drug)
January 2023Transferred the sales of DOXIL Injection 20 mg from Mochida Pharmaceutical Co., Ltd.
May 2023Thai subsidiary OLIC (Thailand) Limited launched the oral contraceptive Nextstellis™
May 2023Launched our company's first dietary supplement LAFILL Folic Acid + Kestose
December 2024Launched dysmenorrhea treatment agent alyssa combination tablets (new drug)
January 2025Started pharmacy sales of the oral contraceptive Nextstellis™ in Thailand
February 1972Launched the adrenocortical hormone preparation DEXAN
April 1978Launched new antibiotics preparations
June 1984Launched topical medicines (ointment and cream)
July 1990Launched prostaglandin E1 preparation ALPROSTADIL ALFADEX for injection
July 1990Launched the antibiotic preparation AMIKACIN SULFATE injection
July 1996Launched the urinary tract and vascular contrast agent OYPALOMIN injection
July 1998Launched the adrenocortical hormone preparation DEXART injection
April 2000Started import and sale of the topical medicine ELTACIN ointment
July 2001Launched the urinary tract and vascular contrast agent IOPAQUE injection
April 2013Launched the biosimilar Filgrastim BS Injection Syringe "F"
November 2016Succeeded the manufacturing and marketing approval of the acute promyelocytic leukemia treatment agent VESANOID Capsules 10 mg from Chugai Pharmaceutical
November 2018Conclusion of an exclusive partnership agreement with Alvotech Holdings for the commercialization of biosimilars in Japan
December 2021Launched the male-pattern hair loss treatment agent DUTASTERIDE tablets
October 2022Succeeded the manufacturing and marketing approval of SULPREP, MINCLEA, FOLIAMIN, and OSVAN from Nihon Pharmaceutical Co., Ltd.
January 2024Launched LENALIDOMIDE capsules, a product jointly developed with Lotus Pharmaceutical Co., Ltd.
May 2024Launched the biosimilar USTEKINUMAB BS 45mg Syringe for S.C. injection "F"
July 2024Succeeded the manufacturing and marketing approval of AZANIN Tablets, CHOLEBINE Tablets / CHOLEBINE Mini, and SURFACTEN from Mitsubishi Tanabe Pharma Corporation